<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507013</url>
  </required_header>
  <id_info>
    <org_study_id>RD 392-03</org_study_id>
    <nct_id>NCT00507013</nct_id>
  </id_info>
  <brief_title>Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose</brief_title>
  <official_title>The QuickClose Study: Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose: a Prospective, Non-Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioDex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The QuickClose study is a prospective, non-randomized study, to evaluate the safety and&#xD;
      efficacy of the QuickClose device using two different dose types of heat exposure.&#xD;
&#xD;
      Patients undergoing a diagnostic angiogram procedure will be treated with the QuickClose&#xD;
      device. Two groups of 20 patients each, will be enrolled consecutively, Group A will complete&#xD;
      enrollment before enrollment into Group B begins. Patients will be monitored until 30 days&#xD;
      after the procedure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary safety endpoint is the incidence of major complications related to method for&#xD;
      achieving hemostasis at the puncture site. The secondary safety endpoint is the incidence of&#xD;
      minor complications related to method for achieving hemostasis at the puncture site. The&#xD;
      primary efficacy endpoint are time to hemostasis, time to ambulation and time to discharge .&#xD;
      The secondary efficacy endpoints are device and procedure success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of complication</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to hemostasis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hemostasis,Surgical</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QuickClose device</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥ 18 years of age&#xD;
&#xD;
          2. The patient or guardian must provide written informed consent&#xD;
&#xD;
          3. The patient must be willing to comply with follow-up requirements&#xD;
&#xD;
          4. The patient has no child bearing potential or has a negative pregnancy test within the&#xD;
             previous 7 days.&#xD;
&#xD;
          5. Patient is eligible for same day discharge&#xD;
&#xD;
        Procedural Inclusion:&#xD;
&#xD;
          1. A intravascular procedure was preformed using 6 Fr introducer&#xD;
&#xD;
          2. The introducer sheath is located in the common femoral artery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Manual compression has been preformed on the ipsilateral arterial site within the&#xD;
             previous 6 weeks&#xD;
&#xD;
          2. Any closure device has been used on the ipsilateral arterial site within the previous&#xD;
             180 days&#xD;
&#xD;
          3. Any reentry of the ipsilateral site is planned within the next 6 weeks.&#xD;
&#xD;
          4. History of surgical repair of blood vessels of the ipsilateral arterial site&#xD;
&#xD;
          5. Significant bleeding diathesis or platelet dysfunction&#xD;
&#xD;
               1. Thrombocytopenia (Plt count ≤ 100,000)&#xD;
&#xD;
               2. Anemia (Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl)&#xD;
&#xD;
          6. Has life expectancy of less than 1 year due to terminal illness&#xD;
&#xD;
          7. Currently being treated for an infection&#xD;
&#xD;
          8. Receiving GP 2b/3a inhibitors or requires warfarin therapy within the last 14 days.&#xD;
&#xD;
          9. INR results &gt; 1.2 on day of procedure&#xD;
&#xD;
         10. Experienced a Myocardial infarction (CK-MB ≥ 2x upper limits of normal) within the&#xD;
             previous 72 hours&#xD;
&#xD;
         11. Received thrombolytic within previous 72 hours&#xD;
&#xD;
         12. Patient is currently enrolled in an investigational device or drug study which&#xD;
             endpoints have not been met.&#xD;
&#xD;
         13. Absent of pedal pulse&#xD;
&#xD;
         14. Pre-existing autoimmune disease (i.e., Lupus, Addison's Disease, Grave's Disease)&#xD;
&#xD;
         15. Has Body Mass Index(BMI) &lt;20, or BMI &gt;40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Segev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Chaim Sheba M.C.</name>
      <address>
        <city>Tel hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>April 22, 2008</last_update_submitted>
  <last_update_submitted_qc>April 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <keyword>vascular closure device</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

